Ignite Creation Date:
2024-05-05 @ 9:39 PM
Last Modification Date:
2024-10-26 @ 10:07 AM
Study NCT ID:
NCT00935480
Status:
COMPLETED
Last Update Posted:
2017-05-12
First Post:
2009-07-08
Brief Title:
IntensVIH Impact Of Therapy Intensification By An Integrase Inhibitor - CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients
Sponsor:
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Organization:
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Study Overview
Official Title:
IMPACT OF THERAPY INTENSIFICATION BY AN INTEGRASE INHIBITOR - CCR5 INHIBITOR ON THE LYMPHOID RESERVOIR FOR HIV-1 IN CHRONICALLY INFECTED PATIENTS
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IntensVIH
Brief Summary:
To determine the efficacy of adding Isentress with or without Celsentri to effective conventional antiretroviral therapy comprising at least 2 reverse transcriptase inhibitors and one boosted protease inhibitor on residual HIV replication and blood cell and gut-associated lymphoid tissue reservoirs reverse transcriptase inhibitors RTIs boosted protease inhibitors PIr
To evaluate the effect of therapy intensification by means of an integrase inhibitor with or without CCR5 inhibitor treatment on the lymphoid reservoir in patients chronically infected with HIV-1 successfully treated with conventional triple therapy measured by
residual plasma replication between 0 and 50 copiesml
intracellular HIV RNA levels in circulating lymphocytes PBMC and lymphocytes in gut-associated rectal lymphoid tissue RL
proviral HIV DNA levels in PBMC and RL
To evaluate the effect of therapy intensification by means of an integrase inhibitor with or without CCR5 inhibitor treatment on the lymphoid reservoir in patients chronically infected with HIV-1 successfully treated with conventional triple therapy measured by
residual plasma replication between 0 and 50 copiesml
intracellular HIV RNA levels in circulating lymphocytes PBMC and lymphocytes in gut-associated rectal lymphoid tissue RL
proviral HIV DNA levels in PBMC and RL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None